Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis
-
Add time:09/28/2019 Source:sciencedirect.com
Background & AimsThe clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) remains subject to debate as definitive randomized controlled trials are lacking. We aimed to determine whether UDCA prolongs liver transplant (LT)-free survival in patients with PBC.
We also recommend Trading Suppliers and Manufacturers of Ursodeoxycholic acid (cas 128-13-2). Pls Click Website Link as below: cas 128-13-2 suppliers
Prev:Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity
Next:Quantum chemical computations of 1,3-PHENYLENEDIACETIC ACID (cas 19806-17-8)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity10/01/2019
- Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH09/27/2019
- Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)09/26/2019
- ArticlesUrsodeoxycholic acid (cas 128-13-2) versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial09/25/2019
- Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease09/24/2019
- Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis09/10/2019
- Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy09/09/2019
-
Health and Chemical more >